Cullinan Therapeutics

(NASDAQ) CGEM

Current Price$13.11

Market Cap$777.76M

Since IPO (2021)-57%

5 Year-60%

1 Year+63%

1 Month-4%

Cullinan Therapeutics Financials at a Glance

Market Cap

$777.76M

Revenue (TTM)

$0.00

Net Income (TTM)

$219.88M

EPS (TTM)

$-3.72

P/E Ratio

-3.45

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$13.11

Volume

380,938.917

Open

$12.70

Price

$13.11

Volume

380,938.917

Open

$12.70

Previous Close

$13.05

Daily Range

$12.67 - $13.14

52-Week Range

$5.68 - $16.74

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$13.11

Volume

380,938.917

Open

$12.70

Previous Close

$13.05

Daily Range

$12.67 - $13.14

52-Week Range

$5.68 - $16.74

CGEM News

CGEM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cullinan Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

109

CEO

Nadim Ahmed

Website

www.cullinantherapeutics.com

Headquarters

Cambridge, MA 02142, US

CGEM Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-44%

Return on Capital

-59%

Return on Assets

-49%

Earnings Yield

-28.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$777.76M

Shares Outstanding

60.53M

Volume

380.94K

Avg. Volume

796.17K

Financials (TTM)

Gross Profit

$311.00K

Operating Income

$241.65M

EBITDA

$241.65M

Operating Cash Flow

$175.75M

Capital Expenditure

$49.00K

Free Cash Flow

$175.80M

Cash & ST Invst.

$377.90M

Total Debt

$2.68M

Cullinan Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$79.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$777.76M

N/A

Market Cap/Employee

$7.01M

N/A

Employees

111

N/A

Net Income

$50.71M

-6.4%

EBITDA

$60.48M

-10.0%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$375.21M

-5.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.90M

+124.1%

Short Term Debt

$780.00K

-40.1%

Return on Assets

-49.04%

N/A

Return on Invested Capital

-58.85%

N/A

Free Cash Flow

$38.12M

-4.1%

Operating Cash Flow

$38.11M

-4.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CBLLCeriBell, Inc.

CBLLCeriBell, Inc.$20.16+4.73%

EHABEnhabit, Inc.

EHABEnhabit, Inc.$13.74-0.04%

RAPTRAPT Therapeutics, Inc.

RAPTRAPT Therapeutics, Inc.$58.01+0.00%

OMEROmeros Corporation

OMEROmeros Corporation$14.60+0.27%

VREXVarex Imaging Corporation

VREXVarex Imaging Corporation$11.65+5.62%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$3.78+0.00%

NMRANeumora Therapeutics, Inc. Common Stock

NMRANeumora Therapeutics, Inc. Common Stock$2.47+9.78%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$94.48-0.00%

NOKNokia

NOKNokia$12.91+0.04%

SOFISoFi Technologies

SOFISoFi Technologies$16.10+0.04%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.63+0.10%

MARAMara Holdings

MARAMara Holdings$11.99+0.12%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.54+0.03%

FFord Motor Company

FFord Motor Company$12.08-0.01%

Questions About CGEM

What is the current price of Cullinan Therapeutics?

Cullinan Therapeutics is trading at $13.05 per share.

What is the 52-week range for Cullinan Therapeutics?

Over the past 52 weeks, Cullinan Therapeutics has traded between $5.68 and $16.74.

How much debt does Cullinan Therapeutics have?

As of the most recent reporting period, Cullinan Therapeutics reported total debt of $2.68M.

How much cash does Cullinan Therapeutics have on hand?

Cullinan Therapeutics reported $88.33M in cash and cash equivalents in its most recent financial results.

What is Cullinan Therapeutics’s dividend yield?

Cullinan Therapeutics does not currently have a dividend yield.

Cullinan Therapeutics

Cullinan Therapeutics Financials at a Glance

CGEM News

Cullinan (CGEM) Q2 R&D Jumps 68%

Why Shares of Cullinan Oncology Jumped This Week

Why Cullinan Oncology Stock Is Skyrocketing Today

CGEM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cullinan Therapeutics

CGEM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cullinan Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CGEM

What is the current price of Cullinan Therapeutics?

What is the 52-week range for Cullinan Therapeutics?

How much debt does Cullinan Therapeutics have?

How much cash does Cullinan Therapeutics have on hand?

What is Cullinan Therapeutics’s dividend yield?

Premium Investing Services